There have been several studies looking at the effects of canagliflozin for type 2 diabetes.
Canagliflozin and Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. For people without diabetes, HbA1c results are usually less than 6 percent, while people with diabetes usually have higher results. In one study, people taking canagliflozin lowered their HbA1c by 0.77 to 1.03 percent, on average (depending on the dose), while people not taking canagliflozin increased their HbA1c by 0.14 percent.
Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes. This includes such problems as heart disease, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. By getting blood sugar levels under control with canagliflozin, it may be possible to decrease the chances for developing these diabetes complications.
Canagliflozin and Blood Sugar Levels
In studies, canagliflozin lowered fasting blood sugar by 27 to 35 mg/dL, on average. Canagliflozin also lowered two-hour postprandial blood sugar (blood sugar two hours after a meal) by 43 to 59 mg/dL, on average.
Canagliflozin and Weight
As an added benefit, people taking canagliflozin lost an average of 2.8 to 3.9 kg (about 6 to 9 lbs), depending on the dosage, over a period of 26 weeks.
Some general considerations to keep in mind during treatment with canagliflozin include the following:
- Canagliflozin comes in tablet form. It is taken by mouth once a day.
- Take this medication shortly before the first meal of the day, as the drug tends to decrease blood sugar levels after meals.
- For the medication to work properly, it must be taken as prescribed.